Accurate diagnosis is vital for the successful management of patients with HCM. Mistakes and delays in diagnosis are common. Hypertrophic cardiomyopathy commonly “masquerades” as asthma, anxiety, mitral prolapse, and coronary artery disease. However, once properly diagnosed, patients with HCM can be effectively managed to improve both symptoms and survival. Today, the diagnosis of HCM relies on the identification of increased left ventricular wall thickness on imaging. Diagnosis is most often made using echocardiographic assessment of LVH, LVOT gradients, systolic and diastolic function, and mitral valve anatomy and function. Cardiac magnetic resonance imaging also has a diagnostic role by determining the extent and location of LVH and the anatomic abnormalities of the mitral valve and papillary muscles. In this program internationally expert faculty will review the importance of accurate and comprehensive imaging in the diagnosis and management of HCM, offering tips and tricks for both performing echocardiography and interpreting echo and CMR scans.
To view the practice tool for ready reference, click here.
Cardiologists, interventional cardiologists, electrophysiologists, cardiac surgeons and other healthcare professionals involved in the treatment and management of patients with hypertrophic cardiomyopathy (HCM)
I. Echocardiography for HCM Imaging
II. Cardiac MRI for HCM Imaging
III. Echocardiography Tips and Techniques for Optimizing Imaging in Patients with or at Risk for HCM
- Improve understanding of the prevalence, pathophysiology, unmet patient needs, and natural course of HCM
- Develop a clear understanding of the implications of undiagnosed, untreated, and undertreated HCM and its associated comorbidities
- Increase confidence and competence in diagnostic skill for recognizing HCM, including echocardiographic evaluation
- Increase familiarity with, and clinical confidence to apply, current, evidence-based guidelines on managing HCM
- Develop a greater awareness of novel and emerging pathophysiology-based mechanisms of action for pharmaceuticals that treat HCM, the clinical data that supports these MOAs, and the impact of these data on guidelines and practice
Theodore Abraham, MD
Meyer Friedman Distinguished Professor of Medicine
Director, UCSF Adult Cardiac Echocardiography Laboratory
University of California San Francisco
San Francisco, California
Prof. Thor Edvardsen
Professor and Head, Department of Cardiology
Oslo University Hospital
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
|Faculty||Relationship Identified With:|
|Theodore Abraham, MD
|Grant/Research Support: Bristol-Myers Squibb; Cytokinetics; Echonous Ultrasound; Tenaya Therapeutics; Imbria; GE HealthCare; Philips Ultrasound|
|Prof. Thor Edvardsen
|Nothing to disclose.|
|Isaac Kwan||Nothing to disclose.|
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Nicole McMenamin and Chelsey Benedek hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit TM.
Clinicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been supported by an independent educational grant from Bristol Myers Squibb.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb do not recommend the use of any agent outside of the labeled indications.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 50% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].